I learned from the Business Times yesterday that Alverix has installed a new CEO, replacing the investor who had the interim role since the funding. A good thing too as neither Startup CEO nor Managing Director of the life sciences group at Safeguard Scientifics is a part-time job. I just had two thoughts on the matter. First to note that the new CEO, James Merselis, worked for just one large company from his early twenties to his mid-forties. He spent those 22 years rising through the ranks of Boehringer Mannheim Diagnostics (NKA Roche Diagnostics.) Not perhaps the career path everyone would suggest to a 22-year-old who asks how to become a startup CEO.
The clichéd wisdom of the search world is that one wants such an executive's introduction to startups to be in someone else's company and that after that first startup experience he or she is more valuable. Certainly his experience at Hemosense has had more liquid results than that at Micronics.
Anyway, my other thought regards the connections by which people end up under consideration for a role like this. I don't have any inside knowledge of how James and the Alverix board got together but I do think this little chain is interesting. Before the spinout from Avago, Alverix entered some sort of partnership with a company called Chembio. James joined the Chembio board this past March. I don't, of course, know how he and the board at Chembio connected but Inverness Medical, to whom he sold Hemosense, has an exclusive deal to market Chembio's products. Social Networking boosters, make of it what you will.